Literature DB >> 4009619

4-Deoxypyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption.

E Marchi, L Montecchi, A P Venturini, G Mascellani, M Brufani, L Cellai.   

Abstract

A series of 4-deoxypyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV derivatives (6-11) were prepared that demonstrated high antibacterial activity suitable for an intestinal disinfectant. These compounds are zwitterionic in nature and are poorly absorbed through the gastroenteric tract but maintain the ability to cross the bacterial cell wall. X-ray crystallographic data are presented to demonstrate the zwitterionic nature of these compounds. The structure-activity relationship of this novel series of antibiotics is discussed and the derivative with the highest ratio between subcutaneous and oral activity (6) was selected for clinical development. At the outset of this work several 3-(quaternary ammonium bromides) (1-5) were prepared and tested for antibacterial activity. These compounds were demonstrated to be too polar to even cross the bacterial cell wall but led to the synthesis of 6-11.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4009619     DOI: 10.1021/jm00145a020

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.

Authors:  Jie Cheng; Yatrik M Shah; Xiaochao Ma; Xiaoyan Pang; Toshiya Tanaka; Tatsuhiko Kodama; Kristopher W Krausz; Frank J Gonzalez
Journal:  J Pharmacol Exp Ther       Date:  2010-07-13       Impact factor: 4.030

2.  The Forgotten Famous: A Tribute to Rififi.

Authors:  Doriano Lamba; Cecilia Bartolucci
Journal:  ACS Med Chem Lett       Date:  2019-12-09       Impact factor: 4.345

3.  Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology.

Authors:  Chinyu G Su; Faten Aberra; Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

4.  In vitro activity of rifaximin against Helicobacter pylori.

Authors:  F Mégraud; F Bouffant; C Camou Juncas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-02       Impact factor: 3.267

Review 5.  Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

6.  Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.

Authors:  Corrado Blandizzi; Giuseppe Claudio Viscomi; Carmelo Scarpignato
Journal:  Drug Des Devel Ther       Date:  2014-12-16       Impact factor: 4.162

Review 7.  Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.

Authors:  L Gatta; C Scarpignato
Journal:  Aliment Pharmacol Ther       Date:  2017-01-12       Impact factor: 8.171

Review 8.  Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs.

Authors:  Roberta Censi; Piera Di Martino
Journal:  Molecules       Date:  2015-10-15       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.